AstraZeneca's antipsychotic drug Seroquel (quetiapine fumarate) does notlead to significant weight gain in patients, even after they have taken the drug for 18 months, according to new clinical data published in the current issue of the International Journal of Psychiatry in Clinical Practice. Frequently associated with some other antipsychotics, significant weight gain can affect treatment compliance and quality of life, as well as contribute to illnesses such as type 2 diabetes, cardiovascular disease and cancer, notes the company.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze